Shailaja Suryawanshi

TL;DR: Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events.

TL;DR: Pembrolizumab prolonged OS versus chemotherapy as second-line therapy for advanced esophageal cancer in patients with programmed death ligand-1 combined positive score (CPS) ≥ 10, with fewer treatment-related adverse events.

TL;DR: Alendronate and estrogen produced favorable effects on BMD, biochemical markers of bone turnover, safety, and tolerability in 425 hysterectomized postmenopausal women with low bone mass, and combined use of alendronates and estrogenproduced somewhat larger increases in BMD than either agent alone and was well tolerated.

TL;DR: Among women who discontinued alendronate and took placebo in the extension, BMD remained higher, and reduction in bone turnover was greater than values at FIT baseline, showing persistence of alendroate's effects on bone.

TL;DR: Alendronate and estrogen produced favorable effects on BMD, biochemical markers of bone turnover, safety, and tolerability in 425 hysterectomized postmenopausal women with low bone mass, and combined use of alendronates and estrogenproduced somewhat larger increases in BMD than either agent alone and was well tolerated.